NovoCure Ltd — Director's Dealing 2022

Mar 8, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2022-03-03

Reporting Person: GROENHUYSEN WILHELMUS CM (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-03	Ordinary Shares	A	21921	—	Acquired	171895	Direct
2022-03-03	Ordinary Shares	S	1301	$74.498	Disposed	170594	Direct
2022-03-04	Ordinary Shares	S	2569	$70.407	Disposed	168025	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-03	Options to Buy Ordinary Shares	$80.59	A	38390	Acquired	2032-02-29	Ordinary Shares (38390.0)	Direct
2022-03-03	Options to Buy Ordinary Shares	$80.59	A	7664	Acquired	2032-02-29	Ordinary Shares (7664.0)	Direct

Footnotes

F1: Represents restricted share units that are scheduled to vest in equal installments on each of March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.

F2: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F3: Options to buy 38,390 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.

F4: Options to buy 7,664 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates.